Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world-Reference-Cited by-同舟云学术

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world

Published:2022-05-11 Issue:2 Volume:109 Page:162-165
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Vodicka Prokop¹,Benesova Katerina¹,Janikova Andrea²,Prochazka Vit³,Belada David⁴,Mocikova Heidi⁵,Steinerova Katerina⁶,Duras Juraj⁷,Karban Josef¹,Hanackova Veronika³,Sykorova Alice⁴,Obr Ales³,Trneny Marek¹

Affiliation:

1. First Department of Medicine Charles University and General University Hospital Prague Czech Republic

2. Department of Hematology and Oncology, Faculty of Medicine Masaryk University and University Hospital Brno Czech Republic

3. Department of Haemato‐Oncology, Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czech Republic

4. 4^th Department of Internal Medicine ‐ Hematology, Faculty of Medicine Charles University and University Hospital Hradec Kralove Czech Republic

5. Department of Internal Medicine – Hematology, Third Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

6. Department of Haemato‐Oncology, Faculty of Medicine Charles University and University Hospital Pilsen Pilsen Czech Republic

7. Department of Hematology Medical Faculty of the Ostrava University and University Hospital Ostrava Czech Republic

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13784

Reference13 articles.

1. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

3. Management of relapsed/refractory DLBCL